Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Complete if Vnoven
 Under the Paperwork Reduction Act of 1995, no persons are required to re 	espond to a collection of information unless it displays a valid OMB control number
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/055,109 PINFORMATION DISCLOSURE **Filing Date** 1/23/2002 STATEMENT BY APPLICANT First Named Inventor Shi et al. M# 3 0 2002 1645 Group Art Unit Sjuse as many sheets as necessary) **Examiner Name** Unknown 3 Sheet **Attorney Docket Number** TM0066-UT of

aminer tials*	Cite No. ¹	U.S. Patent D	Document Kind Code ²		1	······································
11-1	 	Number	(if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	5,093,245		Keith et al.	03/03/1992	
	2	5,366,877		Keith, D.	11/22/1994	
	3	5,459,037		Sutcliffe et al.	10/17/1995	
	4	5,695,937		Kinzler et al.	12/09/1997	
	5	5,712,126		Weissman et al.	01/27/1998	
	6	5,866,330		Kinzler et al.	02/02/1999	
He	7	5,871,697		Rothberg et al.	02/16/1999	
						- whet set -

T		Ι	Foreign Patent Docur	nent		Date of Publication of	Pages, Columns, Lines,	T
Examiner Initials*	Cite No. ¹	Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
AC	- 8	PCT	WO 98/51789	A2& A3	Display Systems Biotech	11/19/1998		
								+
<u> </u>								 -
								+
		1						

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ute for form 1449B	/PTO	E.	ed to respond to a collection of informatio	ete if Known	(1)	,	enrole l
	IFORMATION DISCLOS TATEMENT BY APPLIED (use as many sheets as necessary		3 0 5005	Application Number	10/055,109		Andrew Andrew Andrew	
INF	ORMATION	V Dis	CLOSURE	Filing Date	1/23/2002	All and the second of the seco	eta gantaria etak	1, 200
STA	TEMENT	BŶŶĄ	ANT	First Named Inventor	Shi et al.	33	, 20 € 12	MEH.
				Group Art Unit	1645	3		(1945) (1945)
	(use as many sh	eets as r	ecessary)	Examiner Name	Unknown	18		
Sheet	2	of	3	Attorney Docket Number	TM0066-UT	8		

R ART -	NON PATENT LITERATURE DOCUMENTS	
Cite, No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AA	ADAMS et al., "Complementary DNA sequencing: Expressed sequence tags and human genome project." Science 252:1651-1656, (1991).	
АВ	DEMPSEY et al., "A cardiovascular EST repertoire: progress and promise for understanding cardiovascular disease." Mol. Med. Today 6:231-237, (2000).	
AC	FISHEL et al., "The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer." Cell 75:1027-1038, (1993).	
AD	GRAVES, D., "Powerful tools for genetic analysis come of age." Trends Biotechnol. 17:127-134, (1999).	
AE	GUBLER et al., "A simple and very efficient method for generating cDNA libraries." Gene 25:263-269, (1983).	
AF	KARP, P., "Database links are a foundation for interoperability." Trends Biotechnol. 14:273-279, 1996	
AG	KOYAMA et al., "Structure of a cytotoxic T-lymphocyte-specific gene shows a strong homology to fibrinogen β and γ chains." Proc. Natl. Acad. Sci. USA 84:1609-1613, (1987).	
АН	LEVY-LAHAD et al., "A familial Alzheimer's disease locus on chromosome I." Science 269:970-977, (1995).	
AI	PAN et al., "The receptor for the cytotoxic ligand TRAIL." Science 276:111-113, (1997).	
AJ	PAPADOPOULOS et al., "Mutation of <i>mutL</i> homolog in hereditary colon cancer." Science 263:1625-1629, (1994).	
AK	RICHMOND et al., "Chasing the dream: plant EST microarrays." Curr. Opin. Plant Biol. 3:108-116, (2000).	
	AA AB AC AD AF AG AH AI	 No." item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. AA ADAMS et al., "Complementary DNA sequencing: Expressed sequence tags and human genome project." Science 252:1651-1656, (1991). AB DEMPSEY et al., "A cardiovascular EST repertoire: progress and promise for understanding cardiovascular disease." Mol. Med. Today 6:231-237, (2000). FISHEL et al., "The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer." Cell 75:1027-1038, (1993). GRAVES, D., "Powerful tools for genetic analysis come of age." Trends Biotechnol. 17:127-134, (1999). GUBLER et al., "A simple and very efficient method for generating cDNA libraries." Gene 25:263-269, (1983). KARP, P., " Database links are a foundation for interoperability." Trends Biotechnol. 14:273-279, 1996 KOYAMA et al., "Structure of a cytotoxic T-lymphocyte-specific gene shows a strong homology to fibrinogen β and γ chains." Proc. Natl. Acad. Sci. USA 84:1609-1613, (1987). LEVY-LAHAD et al., "A familial Alzheimer's disease locus on chromosome I." Science 269:970-977, (1995). PAN et al., "The receptor for the cytotoxic ligand TRAIL." Science 276:111-113, (1997). PAPADOPOULOS et al., "Mutation of mutL homolog in hereditary colon cancer." Science 263:1625-1629, (1994).

		1		1		^
Examiner Signature	House	kr.	Chakron	baron	Date Considered	6/19/02_

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, to persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/ INFORMATION DIS STATEMENT BY APP

(use as many sheets as necessary)

of

3

3

Sheet

Complete if Known **Application Number** 10/055,109 73.3 Filing Date 1/23/2002 **First Named Inventor** Shi et al. 1645 Group Art Unit Unknown **Examiner Name** TM0066-UT **Attorney Docket Number**

vaminar	Cita	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	T_
xaminer nitials*	Cite, No.	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
AC	AL	SHERIDAN et al., "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors." Science 277:818-821, (1997).	
	AM	STRAUSBERG et al., "The Cancer Genome Anatomy Project: building an annotated gene index." <u>Trends Genet</u> . 16(3):103-106, (2000).	
	AN	VINCENZ et al, "Fas-associated death domain protein interleukin-1 β-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling." J. Biol. Chem. 272(10):6578-6583, (1997).	
	AO	YAMAMOTO et al., "Use of serial analysis of gene expression (SAGE) technology." J. Immunol. Meth. 250:45-66, (2001).	
	ΑP	ZIPFEL et al., "Complexity of the primary genetic response to mitogenic activation of human T cells." Mol. Cell. Biol. 9(3):1041-1048, (1989).	
Åe	AQ	ZWEIGER et al., "From expressed sequence tags to 'epigemonics': an understanding of disease processes." Curr. Opin. Biotechnol. 8:684-687, (1997).	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.